LLY supply chain intelligence for Eli Lilly and Company: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| INCY | Incyte Corporation | 95% | Reciprocal relationship from INCY graph: ervice institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, purchase directly from our wholesalers. C… |
| ACRS | Aclaris Therapeutics, Inc. | 92% | Reciprocal relationship from ACRS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACRS gra… |
| BOEHRINGER-INGELHEIM | BOEHRINGER-INGELHEIM | 92% | Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim. |
| VTYX | Ventyx Biosciences Inc | 92% | Reciprocal relationship from VTYX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Pursuant to the Merger Agreement, and upon the terms and subject to the condi… |
| GENENTECH-INC | GENENTECH-INC | 90% | Roche receives tiered royalty payments on worldwide net sales ranging in percentages from high single digits to high teens, which we recognize as cost of sales. |
| CRNX | Crinetics Pharmaceuticals, Inc. | 85% | Reciprocal relationship from CRNX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CRNX gra… |
| OPK | OPKO Health, Inc. | 85% | Reciprocal relationship from OPK graph: 6, through its subsidiary Waratah Pharmaceuticals Inc., entered into a worldwide license agreement with Eli Lilly and Company (“Eli Lilly”) to develop and comm… |
| PRQR | ProQR Therapeutics N.V. | 85% | Reciprocal relationship from PRQR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from PRQR graph: — ( ) The effect of changes in foreign exchange rates — — — Other cha… |
| ACIU | AC Immune SA | 72% | Reciprocal relationship from ACIU graph: scussed below). Further, the Civil Monetary Penalties Law imposes penalties against any person or entity that, among other things, is determined to have prese… |
| BCYC | Bicycle Therapeutics plc | 72% | Reciprocal relationship from BCYC graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC gra… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in comb… |
| ECOR | electroCore, Inc. | 72% | Reciprocal relationship from ECOR graph: uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that the primary competitive factors in the p… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a… |
| ELAN | Elanco Animal Health Incorporated | 72% | Reciprocal relationship from ELAN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ELAN graph: services to prevent and treat disease in farm animals and pets. We partner wi… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial.… |
| GYRE | Gyre Therapeutics, Inc. | 72% | Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product can… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industri… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM gra… |
| INSP | Inspire Medical Systems, Inc. | 72% | Reciprocal relationship from INSP graph: Reciprocal relationship from LLY graph: Reciprocal relationship from INSP graph: ely $4.0 million in lost revenue opportunity, most of which we believe was re… |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | Reciprocal relationship from LGND graph: entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of … |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MGNX graph: n exclusive option to license worldwide rights to the research program, upon … |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the developmen… |
| PPCB | Propanc Biopharma, Inc. | 72% | Reciprocal relationship from PPCB graph: Reciprocal relationship from LLY graph: Reciprocal relationship from PPCB graph: Reciprocal relationship from LLY graph: Reciprocal relationship from PPCB gra… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: Reciprocal relationship from LLY graph: Reciprocal relationship from PRME graph: Reciprocal relationship from LLY graph: Reciprocal relationship from PRME gra… |
| QTRX | Quanterix Corporation | 72% | Reciprocal relationship from QTRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from QTRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from QTRX gra… |
| RANI | Rani Therapeutics Holdings, Inc. | 72% | Reciprocal relationship from RANI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from RANI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from RANI gra… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from REGN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from REGN gra… |
| RIGL | Rigel Pharmaceuticals, Inc. | 72% | Reciprocal relationship from RIGL graph: al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or face other difficulties to operate, the… |
| SDGR | Schrödinger, Inc. | 72% | Reciprocal relationship from SDGR graph: performance-based vesting conditions are considered probable as of that date. F-30 Table of Contents (11) . The Company has no obligation to fund Nimbus' loss… |
| SEPN | Septerna, Inc. | 72% | Reciprocal relationship from SEPN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SEPN gra… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $281,860 across 2 awards. 36C25026N0080 AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN; 36C26226N0579 F-18 AMYVID B+4 | Qwen corre… |
| ACIU | AC Immune SA | 92% | Reciprocal relationship from ACIU graph: ave achieved and our goal of a close working relationship with the regulatory agencies, in particular the FDA and the EMA, are intended to facilitate expediti… |
| BOEHRINGER-INGELHEIM | BOEHRINGER-INGELHEIM | 92% | Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim. |
| IMRX | Immuneering Corporation | 92% | Reciprocal relationship from IMRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMRX gra… |
| SPRB | Spruce Biosciences, Inc. | 92% | Reciprocal relationship from SPRB graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SPRB gra… |
| ALMIRALL-S-A | ALMIRALL-S-A | 90% | We receive tiered royalty payments on net sales in Europe ranging in percentages from low double digits to low twenties, which we recognize as collaboration and other revenue. |
| FHTX | Foghorn Therapeutics Inc. | 90% | Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX gra… |
| ACRS | Aclaris Therapeutics, Inc. | 80% | Reciprocal relationship from ACRS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACRS graph: Under the terms of the royalty purchase agreement, we sold to OMERS a portion… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AMPH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AMPH gra… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of the Jardiance product family in the most significant markets and recognize the royalty as collaborat… |
| BEAM | Beam Therapeutics Inc. | 72% | 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (2) Humalog revenue includes insulin lispro. (3) Basa… |
| BEAM | Beam Therapeutics Inc. | 72% | Reciprocal relationship from BEAM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BEAM gra… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (2) Humalog revenue includes insulin lispro. (3) Basa… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | Reciprocal relationship from BMRN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from LLY graph: 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,35… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CAH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CAH graph:… |
| CAH | Cardinal Health, Inc. | 72% | ng at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain websites and other media channels (e.g., social media) with information about our… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: s while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the … |
| CYCN | Cyclerion Therapeutics, Inc. | 72% | Reciprocal relationship from CYCN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CYCN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CYCN gra… |
| ECOR | electroCore, Inc. | 72% | Reciprocal relationship from ECOR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ECOR graph: uster and migraine markets by securing broad market acceptance of our prescri… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements w… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, … |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from LLY graph: ng at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain w… |
| MCK | McKesson Corporation | 72% | ng at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain websites and other media channels (e.g., social media) with information about our… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. Furt… |
| MGTX | MeiraGTx Holdings plc | 72% | Reciprocal relationship from MGTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MGTX graph: acture plasmid DNA – the critical starting material for producing gene therap… |
| MNPR | Monopar Therapeutics Inc. | 72% | Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities … |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the developmen… |
| PPCB | Propanc Biopharma, Inc. | 72% | Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, … |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LLY-DEBT | Debt stack $43.4B | 90% | Market cache reports total debt of $43.4B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LLY-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 4359 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BIOA | BioAge Labs, Inc. | 100.00 | 1 | ['spend'] |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| CMMB | Chemomab Therapeutics Ltd. | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| GANX | Gain Therapeutics, Inc. | 100.00 | 2 |